| Identification | Back Directory | [Name]
Pyrido[3,4-f]-1,4-oxazepine-9-carbonitrile, 4-(3,3-difluoro-2,2-dimethyl-1-oxopropyl)-2,3,4,5-tetrahydro- | [CAS]
2252271-93-3 | [Synonyms]
4-(3,3-difluoro-2,2-dimethyl-propanoyl)-3,5-dihydro-2H-pyrido[3,4-f][1,4]oxazepine-9-carbonitrile
Pyrido[3,4-f]-1,4-oxazepine-9-carbonitrile, 4-(3,3-difluoro-2,2-dimethyl-1-oxopropyl)-2,3,4,5-tetrahydro- | [Molecular Formula]
C14H15F2N3O2 | [MOL File]
2252271-93-3.mol | [Molecular Weight]
295.28 |
| Chemical Properties | Back Directory | [Boiling point ]
469.9±45.0 °C(Predicted) | [density ]
1.30±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
2.66±0.20(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Oditrasertib (SAR443820) is an orally active, BBB-penatrable and selective reversible inhibitor of RIPK1. Oditrasertib can be used in the research of chronic inflammatory central nervous system diseases, such as amyotrophic lateral sclerosis and multiple sclerosis[1][2][3]. | [IC 50]
RIPK1 | [References]
[1] Fidalgo JDV, et al. Preparation of substituted oxazepines and related compounds as RIPK1 inhibitors and uses thereof. WO2018213632A1. 2018-11-22.
[2] Hincelin-Mery A, et al. Safety, pharmacokinetics, and target engagement of a brain penetrant RIPK1 inhibitor, SAR443820 (DNL788), in healthy adult participants. Clin Transl Sci. 2024 Jan;17(1):e13690. DOI:10.1111/cts.13690
[3] Montalban X, et al. Effect of RIPK1 inhibitor, SAR443820, on serum neurofilament light levels in patients with multiple sclerosis: a phase 2 trial design (P6-3.011)[J]. Neurology, 2023, 100(17_supplement_2): 2178. |
|
|